
The Vigil vaccine is a genetically engineered vaccine made from cancer cells acquired from patients during surgery.
Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abraham A. Mitchell Cancer Research Scholar. He specializes in the management of cancers of the ovary, uterus, cervix and lower genital tract. As the Associate Director for Clinical Research, Dr. Rocconi provides leadership and medical expertise to the clinical trials department, reviews and designs clinical research protocols, evaluates safety and efficacy data, analyzes and summarizes data for presentation to regulatory agencies, and provides strategic guidance on non-regulatory clinical trial plans. He is the recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award and the Gynecologic Oncology Young Investigator Research Award. Dr. Rocconi also serves as a scientific expert reviewer for the U.S. Department of Defense Ovarian Cancer Research Program.